CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 48 enrolled
Drug / intervention
Nasal Glucagon +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01997411
NCT01997411Phase 3Completed
CompareCT.gov

Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes

Eli Lilly and Company·interventional·Posted Nov 28, 2013·Updated Aug 29, 2018

In Brief

A Phase 3 clinical trial evaluating Nasal Glucagon and Intramuscular Glucagon for Diabetes Mellitus, Type 1. Completed, enrolled 48 participants across 7 sites.

Detailed Summary

The purpose of this study was to assess how glucagon administered nasally, using a nasal dosing delivery device, works in children and adolescents compared with commercially-available glucagon given by injection. In addition, the safety and tolerability of glucagon given nasally was evaluated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesUnited States
CollaboratorsJaeb Center for Health Research, Locemia Solutions ULC

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 28, 2013
Enrollment StartNov 1, 2013
Primary CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 12.6 years ago

Interventions

Nasal Glucagondrug

Intramuscular Glucagondrug